Abstract
Four different “club drugs” are reviewed: MDMA (methylenedioxymethamphetamine, “Ecstasy”), GHB (gamma-hydroxybutyrate), ketamine, and Rohypnol® (flunitrazepam). The neurobiology, clinical pharmacology, and treatment issues for each are discussed.
Additional information
Notes on contributors
![](/cms/asset/1d321c91-b6ab-4939-b6e6-5f3fcfa66c7f/isum_a_66730_ilg0001.gif)
Gena Covell Britt
Elinore McCance-Katz, Ph.D., is Professor of Psychiatry at Virginia Commonwealth University. She specializes in the treatment of substance use disorders in those with infectious diseases, particularly HIV disease.
![](/cms/asset/faf422c2-6395-4ce1-8424-70137e6d003b/isum_a_66730_ilg0002.gif)
Elinore F. McCance-Katz
Gena Covell Britt, Ph.D., is Assistant Professor of Psychiatry at Virginia Commonwealth University. She has been doing research in the substance abuse field for the past 11 years.